Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Harmony Biosciences Holdings, Inc.
Bear Case (25th pct.)
16.6% vs price
Base Case (Median)
43.1% vs price
Bull Case (75th pct.)
64.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $56.71 | 43.1% | High (40%) |
| PE Comparable | $69.18 | 74.5% | Medium (25%) |
| Growth Trajectory DCF | $60.83 | 53.5% | Medium (20%) |
| Graham Number | $32.26 | -18.6% | Medium (40%) |
| EV/EBITDA | $54.09 | 36.5% | Medium (20%) |
| EV/FCF | $132.59 | 234.5% | Medium (20%) |
| Earnings Power Value | $38.38 | -3.2% | Medium (50%) |
Based on 7 out of 7 methods, HRMY appears undervalued at the current price of $39.64. The base case fair value of $56.71 implies 43.1% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.